Vera Therapeutics (VERA) Stock: Buy, Sell, or Hold?
VERA - Vera Therapeutics, Inc. Class A Common Stock
$35.05
1.45 (4.32%)
▲
5d:
+0.17%
30d:
+16.87%
90d:
+4.16%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $35.89 · last confirmed Sep 9, 2026
Strength: 7.5/10
Get Alerted When VERA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: VERA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: VERA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: VERA is currently trading at $35.05, which is considered extended relative to its 30-day fair value range of $30.97 to $35.01.
Technical Outlook: Technically, VERA is in a downtrend. Immediate support is located at $32.88, while resistance sits at $36.41. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: VERA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $77.64 (+121.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VERA is in a downtrend. Immediate support is located at $32.88, while resistance sits at $36.41. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: VERA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $77.64 (+121.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$30.97 -
$35.01
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.3%)
- BULLISH: Trading 121.5% below Wall St target ($77.64)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$30.97 -
$35.01
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$32.88
Resistance Level
$36.41
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.56
Wall Street Target
$77.64
(+121.5%)
Share & Embed Analysis
Last updated: September 14, 2026 12:13 AM ET
Data refreshes hourly during market hours. Next update: 1:13 AM
Data refreshes hourly during market hours. Next update: 1:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VERA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Marshall Fordyce
SELL
22951 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
